Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission

TOKYO (Reuters) - Japan's Shionogi & Co said on Tuesday a global, late-stage study showed its pill-based treatment for COVID-19 was effective in reducing transmission of the disease. Ensitrelvir, known commercially as Xocova, showed a statistically significant reduction in participants with symptomatic infection after exposure to household contacts with COVID, Shionogi said in a statement. The